Amid the challenges of a global pandemic, parts of the medtech sector were positioned to reap some of the spoils enjoyed by the big pharma players. As the pandemic recedes, the demand for these assays – which were often available free of charge to the general public – has inevitably crashed.
At the midpoint of 2022, the state of the medtech market has little to recommend it, with share prices falling and a stagnant deal-making situation. But the medium-term future remains strong, if not spectacular.
Download our infographic for key insights based on Evaluate Medtech consensus forecasts to 2028.
Download Now
Share
Related Blogs
Understand the context. Data-driven news and analysis for the pharma, biotech and medtech sectors.
Hot-off-the-press, Evaluate has just released its latest annual deep dive into the world of orphan drugs and rare diseases. I had the opportunity to preview the content and make the ...
The US Healthcare system is a vast, unwieldy beast that requires significant navigation by any company in the healthcare space. Whether you’re a Big Pharma, a small biotech or an ...
Dealmaking is a hallmark of the pharma industry. Whether to access innovative therapies, expand into new areas or fill a gap left from a failure in the clinic, pipelines need ...
Markella is part of Evaluate’s competitive intelligence (CI) consulting practice, where she works on a wide range of projects to support CI teams in pharma companies to ensure they stay ...
The number of cell and gene therapy (C>)-based treatments in development has increased significantly over the last two decades and can be expected to continue, driven by the modality-specific market ...